Garner B, Waldeck A R, Witting P K, Rye K A, Stocker R
Biochemistry Group, The Heart Research Institute, Sydney New South Wales 2050, Adelaide South Australia 5000, Australia.
J Biol Chem. 1998 Mar 13;273(11):6088-95. doi: 10.1074/jbc.273.11.6088.
Human high density lipoproteins (HDL) can reduce cholesteryl ester hydroperoxides to the corresponding hydroxides (Sattler W., Christison J. K., and Stocker, R. (1995) Free Radical Biol. & Med. 18, 421-429). Here we demonstrate that this reducing activity extended to hydroperoxides of phosphatidylcholine, was similar in HDL2 and HDL3, was independent of arylesterase and lecithin:cholesteryl acyltransferase activity, was unaffected by sulfhydryl reagents, and was expressed by reconstituted particles containing apoAI or apoAII only, as well as isolated human apoAI. Concomitant with the reduction of lipid hydroperoxides specific oxidized forms of apoAI and apoAII formed in blood-derived and reconstituted HDL. Similarly, specific oxidized forms of apoAI accumulated upon treatment of isolated apoAI with authentic cholesteryl linoleate hydroperoxide. These specific oxidized forms of apoAI and apoAII have been shown previously to contain Met sulfoxide (Met(O)) at Met residues and are also formed when HDL is exposed to Cu2+ or soybean lipoxygenase. Lipid hydroperoxide reduction and the associated formation of specific oxidized forms of apoAI and apoAII were inhibited by solubilizing HDL with SDS or by pretreatment of HDL with chloramine T. The inhibitory effect of chloramine T was dose-dependent and accompanied by the conversion of specific Met residues of apoAI and apoAII into Met(O). Canine HDL, which contains apoAI as the predominant apolipoprotein and which lacks the oxidation-sensitive Met residues Met112 and Met148, showed much weaker lipid hydroperoxide reducing activity and lower extents of formation of oxidized forms of apoAI than human HDL. We conclude that the oxidation of specific Met residues of apoAI and apoAII to Met(O) plays a significant role in the 2-electron reduction of hydroperoxides of cholesteryl esters and phosphatidylcholine associated with human HDL.
人高密度脂蛋白(HDL)可将胆固醇酯氢过氧化物还原为相应的氢氧化物(萨特勒W.、克里斯蒂森J.K.和斯托克R.(1995年)《自由基生物学与医学》18卷,421 - 429页)。在此我们证明,这种还原活性可扩展至磷脂酰胆碱的氢过氧化物,在HDL2和HDL3中相似,不依赖芳基酯酶和卵磷脂:胆固醇酰基转移酶活性,不受巯基试剂影响,并且仅含载脂蛋白AI(apoAI)或载脂蛋白AII(apoAII)的重组颗粒以及分离出的人apoAI均可表现出该活性。伴随着脂质氢过氧化物的还原,在源自血液和重组的HDL中形成了apoAI和apoAII的特定氧化形式。同样,用正宗的亚油酸胆固醇酯氢过氧化物处理分离出的apoAI时,apoAI的特定氧化形式会积累。先前已表明,apoAI和apoAII的这些特定氧化形式在甲硫氨酸残基处含有甲硫氨酸亚砜(Met(O)),并且当HDL暴露于Cu2 +或大豆脂氧合酶时也会形成。用十二烷基硫酸钠(SDS)溶解HDL或用氯胺T预处理HDL可抑制脂质氢过氧化物的还原以及apoAI和apoAII特定氧化形式的相关形成。氯胺T的抑制作用呈剂量依赖性,并伴随着apoAI和apoAII特定甲硫氨酸残基向Met(O)的转化。犬HDL以apoAI作为主要载脂蛋白,且缺乏对氧化敏感的甲硫氨酸残基Met112和Met148,其脂质氢过氧化物还原活性比人HDL弱得多,apoAI氧化形式的形成程度也更低。我们得出结论,apoAI和apoAII特定甲硫氨酸残基氧化为Met(O)在与人HDL相关的胆固醇酯和磷脂酰胆碱氢过氧化物的双电子还原中起重要作用。